

Julien Dumurgier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8172525/publications.pdf>

Version: 2024-02-01

117
papers

4,496
citations

94433

37
h-index

123424

61
g-index

126
all docs

126
docs citations

126
times ranked

6180
citing authors

#	ARTICLE	IF	CITATIONS
1	Association between kidney function and incidence of dementia: 10-year follow-up of the Whitehall II cohort study. <i>Age and Ageing</i> , 2022, 51, .	1.6	29
2	Association of APOE ϵ 4 with cerebral gray matter volumes in non-demented older adults: The MEMENTO cohort study. <i>NeuroImage</i> , 2022, 250, 118966.	4.2	11
3	Telemedicine in French Memory Clinics During the COVID-19 Pandemic. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 525-530.	2.6	3
4	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2022, 18, 1868-1879.	0.8	26
5	Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	6.2	12
6	A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging. <i>Neurology</i> , 2022, 99, .	1.1	8
7	Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. <i>Alzheimer's and Dementia</i> , 2021, 17, 755-767.	0.8	81
8	The association of APOE ϵ 4 with cognitive function over the adult life course and incidence of dementia: 20-year follow-up of the Whitehall II study. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 5.	6.2	60
9	Sex differences and the role of education in cognitive ageing: analysis of two UK-based prospective cohort studies. <i>Lancet Public Health</i> , The, 2021, 6, e106-e115.	10.0	45
10	[¹⁸ F]FDG PET may differentiate cerebral amyloid angiopathy from Alzheimer's disease. <i>European Journal of Neurology</i> , 2021, 28, 1511-1519.	3.3	8
11	Cerebrospinal Fluid Biomarkers in Patients With Alcohol Use Disorder and Persistent Cognitive Impairment. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 561-565.	2.4	8
12	Neurofilaments as Emerging Biomarkers of Neuroaxonal Damage to Differentiate Behavioral Frontotemporal Dementia from Primary Psychiatric Disorders: A Systematic Review. <i>Diagnostics</i> , 2021, 11, 754.	2.6	7
13	Brain Glucose Metabolism in Cerebral Amyloid Angiopathy. <i>Stroke</i> , 2021, 52, 1478-1482.	2.0	3
14	Association Between Age at Diabetes Onset and Subsequent Risk of Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1640.	7.4	135
15	Association of sleep duration in middle and old age with incidence of dementia. <i>Nature Communications</i> , 2021, 12, 2289.	12.8	254
16	Comparison of the predictive accuracy of multiple definitions of cognitive impairment for incident dementia: a 20-year follow-up of the Whitehall II cohort study. <i>The Lancet Healthy Longevity</i> , 2021, 2, e407-e416.	4.6	2
17	Terminal decline in objective and self-reported measures of motor function before death: 10 year follow-up of Whitehall II cohort study. <i>BMJ</i> , The, 2021, 374, n1743.	6.0	17
18	Timeline of pain before dementia diagnosis: a 27-year follow-up study. <i>Pain</i> , 2021, 162, 1578-1585.	4.2	13

#	ARTICLE	IF	CITATIONS
19	The Diagnostic Value of a Short Memory Test: The TNI-93. <i>Journal of Alzheimer's Disease</i> , 2021, , 1-11.	2.6	1
20	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. <i>JAMA Neurology</i> , 2021, 78, 1471.	9.0	204
21	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	7
22	Hyperuricemia, Gout, and the Brain—an Update. <i>Current Rheumatology Reports</i> , 2021, 23, 82.	4.7	17
23	Current status and quantitative results of the AMYPAD prognostic and natural history study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
24	Social inequalities in multimorbidity, frailty, disability, and transitions to mortality: a 24-year follow-up of the Whitehall II cohort study. <i>Lancet Public Health</i> , The, 2020, 5, e42-e50.	10.0	147
25	Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 123.	6.2	33
26	CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 88.	6.2	20
27	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. <i>PLoS Medicine</i> , 2020, 17, e1003289.	8.4	39
28	Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 168.	6.2	7
29	CSF levels of the BACE1 substrate Neuregulin1 correlate with cognition and synaptic biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e037097.	0.8	0
30	Memory assessment in illiterate patients: The diagnostic value of the TNI 93. <i>Alzheimer's and Dementia</i> , 2020, 16, e042059.	0.8	0
31	Current status and quantitative results of the AMYPAD prognostic and natural history study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044711.	0.8	0
32	Risk prediction models for dementia: role of age and cardiometabolic risk factors. <i>BMC Medicine</i> , 2020, 18, 107.	5.5	38
33	Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 903-911.	2.6	9
34	Epidemiology of neurological diseases in older adults. <i>Revue Neurologique</i> , 2020, 176, 642-648.	1.5	45
35	Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease. <i>Neurology</i> , 2020, 95, e953-e961.	1.1	50
36	Healthy behaviors at age 50 years and frailty at older ages in a 20-year follow-up of the UK Whitehall II cohort: A longitudinal study. <i>PLoS Medicine</i> , 2020, 17, e1003147.	8.4	34

#	ARTICLE	IF	CITATIONS
37	Clinical features related to CSF level of amyloid A β 242 and A β 240 proteins in presence of lobar microbleeds. <i>Revue Neurologique</i> , 2020, 176, 864-867.	1.5	2
38	Title is missing!. , 2020, 17, e1003289.		0
39	Title is missing!. , 2020, 17, e1003289.		0
40	Title is missing!. , 2020, 17, e1003289.		0
41	Title is missing!. , 2020, 17, e1003289.		0
42	Title is missing!. , 2020, 17, e1003289.		0
43	Title is missing!. , 2020, 17, e1003289.		0
44	Title is missing!. , 2020, 17, e1003289.		0
45	Title is missing!. , 2020, 17, e1003147.		0
46	Title is missing!. , 2020, 17, e1003147.		0
47	Title is missing!. , 2020, 17, e1003147.		0
48	Title is missing!. , 2020, 17, e1003147.		0
49	Title is missing!. , 2020, 17, e1003147.		0
50	Association of ideal cardiovascular health at age 50 with incidence of dementia: 25 year follow-up of Whitehall II cohort study. <i>BMJ: British Medical Journal</i> , 2019, 366, l4414.	2.3	117
51	How many patients are eligible for disease-modifying treatment in Alzheimer's disease? A French national observational study over 5 years. <i>BMJ Open</i> , 2019, 9, e029663.	1.9	16
52	Diagnosis associated with Tau higher than 1200 pg/mL: Insights from the clinical and laboratory practice. <i>Clinica Chimica Acta</i> , 2019, 495, 451-456.	1.1	13
53	What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France. <i>BMJ Open</i> , 2019, 9, e026380.	1.9	17
54	Biomarker profiles of Alzheimer's disease and dynamic of the association between cerebrospinal fluid levels of β -amyloid peptide and tau. <i>PLoS ONE</i> , 2019, 14, e0217026.	2.5	18

#	ARTICLE	IF	CITATIONS
55	Frontotemporal dementia is the leading cause of τ /T+ profiles defined with $A\beta_{42/40}$ ratio. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 161-169.	2.4	8
56	Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. Neurobiology of Aging, 2019, 78, 178-185.	3.1	54
57	CSF level of τ -amyloid peptide predicts mortality in Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 29.	6.2	19
58	O2501: CEREBROSPINAL FLUID SYNAPTIC VESICLE GLYCOPROTEIN 2A IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P545.	0.8	2
59	A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimer's Disease. Neuroscience, 2019, 420, 136-144.	2.3	25
60	Blood-Based Kinase Assessments in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 338.	3.4	11
61	Prevalence of amyloid β pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	5.3	132
62	Alcohol consumption and risk of dementia: 23 year follow-up of Whitehall II cohort study. BMJ: British Medical Journal, 2018, 362, k2927.	2.3	150
63	Relevance of $A\beta_{42/40}$ Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale. Frontiers in Aging Neuroscience, 2018, 10, 138.	3.4	59
64	Distribution of Cerebrospinal Fluid Biomarker Profiles in Patients Explored for Cognitive Disorders. Journal of Alzheimer's Disease, 2018, 64, 889-897.	2.6	9
65	Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers. Current Alzheimer Research, 2018, 15, 691-700.	1.4	5
66	Biomarqueurs du liquide cÃ©brospinal dans la maladie d'Alzheimer. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 307-320.	0.0	1
67	Gait Speed and Decline in Gait Speed as Predictors of Incident Dementia. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, glw110.	3.6	74
68	Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: Results from a meta-analysis and exploratory meta-regression analysis. Ageing Research Reviews, 2017, 35, 63-73.	10.9	182
69	Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults. Journal of Alzheimer's Disease, 2017, 60, 1451-1459.	2.6	80
70	Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. Neurobiology of Aging, 2017, 59, 220.e1-220.e9.	3.1	116
71	PKR involvement in Alzheimer's disease. Alzheimer's Research and Therapy, 2017, 9, 83.	6.2	52
72	Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein. Journal of Alzheimer's Disease, 2016, 51, 905-913.	2.6	21

#	ARTICLE	IF	CITATIONS
73	Time Orientation and 10 Years Risk of Dementia in Elderly Adults: The Three-City Study. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1411-1418.	2.6	12
74	Primary Progressive Aphasia in the Network of French Alzheimer Plan Memory Centers. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1459-1471.	2.6	28
75	The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 41.	6.2	121
76	Seizures in dominantly inherited Alzheimer disease. <i>Neurology</i> , 2016, 87, 912-919.	1.1	81
77	Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. <i>Neurology</i> , 2016, 87, 920-926.	1.1	86
78	Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 27.	6.2	18
79	The role of attention in emotional memory enhancement in pathological and healthy aging. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2016, 38, 434-454.	1.3	10
80	SORL1 rare variants: a major risk factor for familial early-onset Alzheimer's disease. <i>Molecular Psychiatry</i> , 2016, 21, 831-836.	7.9	96
81	IC-P-162: Entorhinal, parahippocampal, and inferior temporal F18-T807 SUVR correlates with CSF total tau and tau T181P in cognitively normal elderly. , 2015, 11, P109-P109.		2
82	Cerebrospinal fluid amyloid- β 42/40 ratio in clinical setting of memory centers: a multicentric study. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 30.	6.2	101
83	Pro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2015, 6, 168.	2.4	10
84	O4-01-04: Entorhinal, parahippocampal, and inferior temporal F18-T807 SUVR correlates with CSF total tau and tau T181P in cognitively normal elderly. , 2015, 11, P267-P267.		1
85	Emotional memory enhancement in respect of positive visual stimuli in Alzheimer's disease emerges after rich and deep encoding. <i>Cortex</i> , 2015, 65, 89-101.	2.4	19
86	Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline. <i>Journal of Psychiatry and Neuroscience</i> , 2015, 40, 151-161.	2.4	75
87	Gait Decline. <i>Hypertension</i> , 2015, 66, 263-264.	2.7	2
88	Screening for cognitive and affective dysfunction in patients suspected of mild cognitive impairment. <i>International Journal of Geriatric Psychiatry</i> , 2014, 29, 936-942.	2.7	7
89	A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 38.	6.2	44
90	Lipid-Lowering Drugs Associated With Slower Motor Decline in the Elderly Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2014, 69A, 199-206.	3.6	20

#	ARTICLE	IF	CITATIONS
91	Change in Fast Walking Speed Preceding Death: Results From a Prospective Longitudinal Cohort Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2014, 69A, 354-362.	3.6	41
92	Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. , 2014, 10, S390-S394.e2.		58
93	Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study. Journal of Neurology, 2014, 261, 144-151.	3.6	56
94	Biomarkers and acute brain injuries: interest and limits. Critical Care, 2014, 18, 220.	5.8	37
95	The screening of Alzheimer's patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials. Journal of Neurology, 2014, 261, 1187-1195.	3.6	11
96	Increased Cerebrospinal Fluid Tau Levels in Logopenic Variant of Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 39, 611-616.	2.6	9
97	P1-129: CSF AD BIOMARKERS IN MEMORY CLINIC PATIENTS: THE EP.L.M.FR STUDY. , 2014, 10, P347-P347.		0
98	O1-09-01: IMPACT OF CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER'S DISEASE IN CLINICAL PRACTICE: A MULTICENTRIC STUDY. , 2014, 10, P146-P147.		0
99	P2-113: CSF AMYLOID- β 42/40 RATIO IN CLINICAL SETTINGS: A MULTICENTRIC STUDY. , 2014, 10, P512-P512.		0
100	Exacerbated CSF abnormalities in younger patients with Alzheimer's disease. Neurobiology of Disease, 2013, 54, 486-491.	4.4	14
101	Relationship between blood pressure, cognitive function and education level in elderly patients with diabetes: A preliminary study. Diabetes and Metabolism, 2013, 39, 418-423.	2.9	6
102	Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. Alzheimer's and Dementia, 2013, 9, 406-413.	0.8	63
103	Motor function in the elderly. Neurology, 2013, 81, 417-426.	1.1	48
104	Cognitive function after several years of antiretroviral therapy with stable central nervous system penetration score. HIV Medicine, 2013, 14, 311-315.	2.2	29
105	Impact of the 2008-2012 French Alzheimer Plan on the Use of Cerebrospinal Fluid Biomarkers in Research Memory Center: The PLM Study. Journal of Alzheimer's Disease, 2013, 34, 297-305.	2.6	51
106	Cerebrospinal Fluid PKR Level Predicts Cognitive Decline in Alzheimer's Disease. PLoS ONE, 2013, 8, e53587.	2.5	46
107	Oxidative stress increases BACE1 protein levels through activation of the PKR-eIF2 γ pathway. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 885-896.	3.8	139
108	New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer's disease. BMC Neuroscience, 2012, 13, 84.	1.9	8

#	ARTICLE	IF	CITATIONS
109	Increased Cerebrospinal Fluid Levels of Double-Stranded RNA-Dependant Protein Kinase in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2012, 71, 829-835.	1.3	52
110	MRI atrophy of the caudate nucleus and slower walking speed in the elderly. <i>NeuroImage</i> , 2012, 60, 871-878.	4.2	62
111	Muscle magnetic resonance imaging sensitivity does not decrease in chronic, mild, or proximal lower limb neuropathies. <i>Muscle and Nerve</i> , 2012, 45, 659-667.	2.2	7
112	Impact of recommendations on the initial therapy of Parkinson's disease: A population-based study in France. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 543-546.	2.2	14
113	CSF A β ¹⁻⁴² Levels and Glucose Metabolism in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 845-851.	2.6	20
114	Hypertension and lower walking speed in the elderly: the Three-City study. <i>Journal of Hypertension</i> , 2010, 28, 1506-1514.	0.5	73
115	Inverse association between CSF A β ¹⁻⁴² levels and years of education in mild form of Alzheimer's disease: The cognitive reserve theory. <i>Neurobiology of Disease</i> , 2010, 40, 456-459.	4.4	30
116	Slow walking speed and cardiovascular death in well functioning older adults: prospective cohort study. <i>BMJ: British Medical Journal</i> , 2009, 339, b4460-b4460.	2.3	274
117	Restless legs syndrome is frequently overlooked in patients being evaluated for polyneuropathies. <i>European Journal of Neurology</i> , 2007, 14, 788-792.	3.3	54